Thinking Differently About Addiction and Mental Health — Dr. Nora Volkow | Transcription

Transcription for the video titled "Thinking Differently About Addiction and Mental Health — Dr. Nora Volkow".

1970-01-01T03:30:19.000Z

Note: This transcription is split and grouped by topics and subtopics. You can navigate through the Table of Contents on the left. It's interactive. All paragraphs are timed to the original video. Click on the time (e.g., 01:53) to jump to the specific portion of the video.


Introduction

Intro (00:00)

Dr. Volkoff, it is lovely to see you. Thank you for making the time to be on the show. Thanks for being here. >> Team, it's a pleasure. Thanks for having me.


Nora'S Background And Views On Science And Drug Addiction

Cadaver homework (00:23)

>> Absolutely. I wanted to say before we launch into the full conversation, a sincere thanks to you and the entire NIDA team, because I have found addiction to be very near and dear to me in the sense that my uncle died of alcohol-induced cardomyopathy, one of my aunts died of alcohol and percocet as an overdose, one of my best friends growing up died of a fentanyl overdose. So this is a subject that I think, not surprisingly to anyone listening is incredibly important and I've just had the opportunity to see it in very close quarters. So I wanted to start with just thanking you for doing the work that you do. So that's step number one. I thought then I would take a very hard left turn and ask you about cadavers specifically. I read that you, when you were quite young, I asked your father if you could bring a cadaver home to dissect. His answer was yes and that his answer was generally yes to anything science related. Could you just flesh this story out a little bit, provide a little more context? >> Absolutely. And first of all, I'm sorry for the loss of your family relatives and your friend. I mean, it is very tragic and that's why I mean, I'm so devoted to the whole subject because it shouldn't be. I mean, people shouldn't be dying from addictions and yet they do and there are many factors that if we could change, then we wouldn't be losing these lives. So let me jump into the question that you call left side or right sided. My father is a scientist. And so he was obsessed of having his daughters, he didn't have a son, so he was obsessed of having the daughters go into science. And I was the one that I have another sister who was then in high school, but I was the one in medical school and I wanted to do research. And I was absolutely fascinated by the human body and anatomy. And I just marvel about the beauty of how our bodies are constructed. So in the classes we have to take anatomy and we work hard to dissect actually a basically the section on people who have died on corpses. But I didn't have enough time and I wanted, I'm very obsessive. Whenever I do things, I do them compulsively. So I wanted to be able to do that right. And based on the time limits that we have at school, it was going to be impossible. We would be able to each one of us, dissect for example, one extremity. And so I asked my father if I could bring a corpse that I could do autopsy. And my father had a laboratory in the house. So and he said, yes. But then my mother and my sisters rebelled and I said, if Nora brings a corpse into the house for her anatomy classes, then we're leaving the house. And that was very categorical. I lost. That's it. No more.


The Trotsky connection. (03:33)

So I'm going to come back to the obsessive focus and following the trail where it leads. I'm going to come back to that. But before I do, perhaps you could just describe where you grew up, where you were at the time, and how someone or a family with the last name Volkov, which to most people would perhaps bring up connotations of certain types of origins, end up in where you ended up in terms of your formative years. I was in Mexico City. I was born in Mexico City. I went to medical school in Mexico City. And it was until I was finishing medical school that I left Mexico to go to Paris, then to the jungle. And then I went to New York for my training in psychiatry. And the reason why actually I ultimately was born in Mexico City, it's interesting. It's driven by, I always say, the belligerent nature of men. Because my father is a grandson of Leon Trotsky. And the only place that gave political asylum to Leon Trotsky was Mexico. And my mother, who was born in Madrid, ended up in Mexico because also Mexico was the place that gave asylum to the children of the people that were fighting against Franco in Madrid. So Madrid was going to be bombarded by the Franco forces. So the government of Mexico, in an attempt to save those children, offer asylum to the children to be brought from Madrid into Mexico at the care of the Mexican government. And so that's how the two families came together. My father came to Mexico as an orphan because and Trotsky basically had taken the responsibility of him. His mother had committed suicide. His father had been sent to a concentration camp by Stalin. And so the only relative that he had was Trotsky. So he came to Mexico because that was his family. And he was 12 years old when he came to Mexico. And that's how he ended up in Mexico. My mother came to Mexico when she was 18 years of age, coming with her family to look for her two brothers who had come and his little children as part of the asylum to the children that were in Madrid. And they met. And that's how for Twitter's history is. They met, they fell in love. And then they had four daughters. And I was the second one of them. And we actually lived in the house where Trotsky had been killed. Because my father took the responsibility to ensure that the house where Trotsky lived will be left as a museum so that there would be a historical memory of what tyranny can do. The tyranny of Stalin and basically the extermination of all of his enemies, which of course, one of his main ones, and he had basically aimed to destroy the family of Trotsky up to the third generation, which would have ended with my father. But it would have ended with us, actually, the third generation he saw. And they tried to kill my father. And my father was a little child, but they didn't succeed. So, and then by my time I was born, which is the third generation, no one has tried to kill me, fortunately, not from the Stalin era. But I shouldn't be so slippant about it. I mean, it's a very serious issue. And of course, it has followed our family. And at one point, when I was a medical student, I wanted to go to Russia, to study, because I was given a scholarship and my father really freaked out. And at that point, is when I was basically made aware, I said, "No, right, you cannot do that. You're also going to be putting your father in a very awkward position because he can be basically a black male." And there is this curse that Stalin had said that he would persecute up to the third generation. And that's how I ended up in Mexico City and where I went to school. And until I did my training in psychiatry. So I would love to expand on this just a little bit for people who may not recognize the name Leon Trotsky. So number one, we won't go into a huge Wikipedia page on Leon Trotsky. But people should read the basics and find him online. Very historically notable, very important, as you mentioned, as opposition of sorts with respect to some very powerful figures in Soviet history. And he also, based on my reading, please correct me if I'm wrong, but survived multiple assassination attempts and then was finally killed, but not immediately by someone with an ice axe that penetrated his head by something like seven centimeters, but still managed to subdue with his guards, the attacker. And he just seems like such a force of nature and such a powerful figure to begin with. And so to have that in your lineage, I would just be so curious to know how all of that has informed if you feel like it has the way you relate to the world. Or even think about history or voicing your own opinion, anything like that. Absolutely. And there's no way it doesn't influence you. And be aware that that's a little girl I was living in that house. And so I was surrounded by not just the knowledge that it was my father's grandfather. And I had basically, well, until I was seven, eight years old, I also, his second wife was living in the house, Natalia, who became a very dear person to me. So when you are born into a house where you know that you have a relative that did something that was very motivated towards improving the base, the next generations, the chances that next generations had that they were committed to a more just and fair society, that is ingrained into your brain. And both my parents were very systematic as making us aware that we do have a responsibility that each one of us as an individual should be recognized that we are part of a social system, where how you act has consequences and that your ask can actually significantly improve or negatively affect the life of others. So we, all of us, my three sisters and I have that very much ingrained into our motivation and how we live our lives. And so for me, that has been crucial. So I become very, I mean, particular, and this is something I've always had. I'm very sensitive to people, the most vulnerable. I mean, it just generates this drive and trying to help, trying to make a very intolerant of injustices. I've always been. And so it drives me crazy. It activates my amygdala when I see someone improperly treated. And obviously, as you grow up and you have different, you find yourselves in positions where you say, what can I do to help? And that has ultimately led me to take this position of, took me to take the position of director of the National Institute on Drug Abuse. Because I realized that it would put me in a leadership position where I could influence the knowledge that was derived in order to affect policies that would lead to a better opportunity for people suffering from substance use disorder. So that's, that's fundamental to me. And that came from my historical background and upbringing.


How Nora’s father viewed the role of science. (12:16)

What did your father feel the role or responsibility of scientists was? I'm wondering, I suppose, why he said yes to most things or all things science related. Maybe he said yes to most things for you. I have no idea. But if it happened to be pretty specific to science, why did he do that? Why was it important in his mind? I think a lot about it because my father, you know, when we were growing up, he could never ever speak about Trotsky. And we were not allowed to ask questions because it was felt that it was just too painful for him to speak up. And the first time he did an interview about his experience with Trotsky, was when I was, I think it must have been 17 years of age or 16 years of age. And that was a turning point for him where he started to speak about it. And I think my father, an extraordinary individual, I mean, with an amazing resilience, was, was using certain mechanism to try to deal with the suffering. I mean, his mother committed suicide when he was living with her. I mean, he lost his father to a concentration camp. His sister was left behind in Russia because Stalin did not allow his mother to take, yeah, basically only allowed him to take one of the two children. And so the mother selected the one that was younger, which was my father. And then when he loses the mother, he goes and lives with an uncle. And the uncle is killed by, by Stalin while in Paris. And then he ends up with Trotsky and Trotsky is assassinated. And basically my father is coming into the house when Merkader, who's the killer, is inside. And he hears him, don't let Sieva, which is the name of my father, see me. So he has the clarity of mind to recognize, he doesn't want my father to see him all covering blood. So if you think about what it must mean for a child to go this, all of these experiences, I think you have to develop mechanism of protection. And in that respect, my view is that science provides it because science tends to be very black and white. I mean, it's not really black and white. I mean, the physical sciences, mathematical sciences are black and white. Biology is more gray there, but you can extract objective information that is reproducible. And I think that gives you a sense of solidity. And I think that this may be one of the reasons why my father was so attracted to science. And what I can tell you, he was very categorical. He did not want any one of his daughters to go into politics. He was black and white, no politics. And his perspective was that the family already had paid a very, very big price because of politics. And so he really didn't want to. So in that respect, of course, science offered this ideal profession where people were driven by looking and trying to understand the truth of things in objective ways, where there was not that subjective element where things can creep in and rapidly be influenced by one person's perspective. Now, this is me speculating about why my father was so driven into the science. It may just be that he loved science because it's a fantastic field. Science is basically you are moving your curiosity to try to understand the world and they pay you for it. So it's a great, a great. So I am making a speculative leap because I have thought about it, like to sort of ask me. But at the same time, I have to recognize that it may also just be that he loved science because he's a curious, very curious person. I'd love to look at other influences in your thinking and trajectory.


Julian Villarreal. (16:22)

And the name I would like to invoke is Julian Vial and I did check the pronunciation before we started for people wondering. And I would love to know who this person was and what influence he had on you, if you could describe. Daniel Julian was a pharmacologist that was working in a pharmaceutical company. And he was a physician and a PhD in pharmacology who had gone to Michigan University for his PhD. And I ended up with him because as a medical student, I knew I wanted to do research. And so I started to volunteer with one of the major scientists in Mexico, Tamajo, who was doing work on autopsies and tissue pathologies. He was a pathologist. And he said, "No, you like behavior. You like drugs. You like the brain. Let me introduce you to someone that will basically have better background than mine." And so he introduced me to Julian Vial. And immediately I hit it off with Julian. And what intrigued me so much about Julian was that he thought outside the box completely. And that resonated totally with me. And he was interested at that time. His research was on trying to understand what were the mechanisms that account for the tolerance to opioids and the mechanisms that account for the withdrawal that emerges when someone becomes physically dependent to opioids. And his idea was that if you have these models and you could understand them, then you would be able to develop an opioid medication that would not be addictive, that would not produce tolerance, that would not produce withdrawal. Many pharmacologies went into that whole field. And certainly what I can tell you as of now, no one has succeeded on getting an opioid medication that is not addictive and that doesn't produce tolerance or withdrawal. But the models that he was using and the way that he was challenging me, which was very, very quantitative, he was always trying to figure out a way of quantifying behavior in animals that then could be used to predict the responses to drugs. How did Julian encourage you to think differently? Well, he was introducing me to a lot of the analytical methods to be able to define variables. I mean, I realized this was very much before its time. Right now, for example, a lot of the analysis that we do employ vectors as a means to actually describe a trajectory of something more than one point. And he was introducing me to those technologies and says, Nora, learn about it and he would give me books so that you can try to see how you apply them to the measures you are taking on the animal experiments. So he opened in my brain the whole curiosity of using quantitative analysis in ways beyond the traditional very simplistic statistical methods that we use. And this is something that now is fundamental for the type of work that we are doing in many fields of science. But for me, as someone that is in neurosciences and neuroimaging, it is crucial to basically enable those to understand and to actually integrate databases that are very, very diverse and distinct. So that I owe to Julianne. I mean, he would challenge me. He would basically give me questions that I that would make me think. And that's what I like. And I actually, he taught me that. And this is something that I, as a mentor now of John scientists, I basically want, I put them in positions where I force them to think and to think differently. And I mean, for example, one of the questions I always go, I mean, you have students and postdocs and they present me the data and I ask them, well, what do you make of it? And they give me an explanation. And I said, okay, now I want you to give me the most outrageous explanation that you can get me of this data in order to force them to think differently. Because there is a predictive element in a lot of the things that is a reflection of the influence of others. And I want that innovative way that association that others have not done. I want to encourage them to play with it. Right. Because as a mentor, especially a mentor who is highly respected by your mentees or postdocs or ever might be, it would be very easy to correct them. And perhaps in some respects, force your perspective on them, but that doesn't help them develop the muscle of thinking differently in the way that you're describing by asking those types of probing questions, which makes all the sense in the world. Yeah, but there's also a selfish component into it. I think that, I mean, for me, it's totally uninteresting to hear a response that I already would have thought myself. So, and I think that brains work better when you expose them to unexpected stimuli. So, I actually, I think that the scientific creativity is enriched by having that basically playing with ideas and concepts. And I encourage it a lot. And so, we have team meetings where I really probe them for people to get into those spaces. And so, it's crucial that you empower them, you make them feel actually confident because otherwise, people don't dare. They feel intimidated that they may say something that others will think it's stupid. And that's so very common when you are in groups. People don't want to be seen as saying something that will make them feel embarrassed. And to me, I always actually start meetings and says, "Look, guys, we're here to basically push the limit." So, please do not feel embarrassed. If you don't speak Apple, never have an opportunity to understand whether that idea may go through. So, it's something I always push, whether it is with people or my mentors or I'm organizing it with experts, I do like to get that going. You have a well-established history, I would say, of pushing the limits and knowing when to push.


A perspective of perseverance. (23:31)

So, I would like to just read something I found from the Washington Post. It's just a few paragraphs and then I'll ask a question related to it. Here we go. In 1984, she, that is you, left NYU for an assistant professorship at the University of Texas Health Science Center at Houston, expecting to continue her research. And then they're quoting you. They had a fantastic imaging center, Volkoff recalls, but as it happens, "There wasn't a single schizophrenic in the university hospital." End quote. What the hospital did have was cocaine addicts. So, you adapted. And I'll summarize a little bit here or just abbreviate, but you said, "I was probably the first person to use these new technologies for the investigation of drugs of abuse," she says. But her work was ignored initially, especially her seminal paper, "Documenting Strokes in the Brains of cocaine abusers." And then this is a quote of view. "I started to present these data at meetings and people didn't believe it because there was no evidence that cocaine was toxic," she says. "That's fine," I said, "because this is what the data show." She applied for a grant from NIDA. Of course, everything comes full circle, but she applied for a grant from NIDA to pursue her research and was turned down. It took three years before the British Journal of Psychiatry finally published her paper. And then the closing quote from you in this section is, "This is what happens when you come up with things before their time." And my question for you is, what was the experience like and what was your inner talk like going through this sequence of events and having people dismiss, having people reject over that period of time? What was that like for you? And how did you keep going? Well, I'm a very perseverant person and I never give up. So the perspective is on this issue has always been like that. And that finding, actually, I'm still working on that to try to understand why how cocaine affects and producing these strokes and how we can prevent them and how we can help people. But at that time, I was very young. And you know, you have this sense of you trust the system and you believe, "Well, maybe I'm not good enough." And you haven't consolidated the belief in yourself, right? I mean, because you are just basically recently trained, you are using... No one had used that technology. So at that point, there was this belief that cocaine was safe. So here comes this person showing these data on images that others had never seen. And with the background that cocaine was at that time felt to be safe. And I submitted it to the New England Journal of Medicine, which is the most important medical journal, clinical medical journal. They review it and they came back again saying, "Well, there's really no evidence that cocaine can be damaging to the blood vessels." They were completely wrong. And now it's clear, I mean, all of that is history. No one will question that cocaine, as well as other stimulant drugs, produces vascular damage and pathology. But it is the way that science goes. And you sort of say science should be guided by data, but science has a religious nature to it also. And once a model is created, it becomes very difficult to change it. So I need to take a long, long time for concepts that have been consolidated as accepted as the truth to be questioned. And I see it. I mean, it happened to me there, but I see it constantly. That statement that I stated there is very, very valid. If you come up with something that it's ahead of its time, you're going to have trouble getting it accepted. And you may not actually necessarily be recognized for it when it becomes everyday life, then we say, "Well, what's the big deal?" That's in the nature of the scientific progress. But as someone that is directing and allocating resources for science, I am very sensitive to ensure that if there are situations where there may be something that is very innovative, that others are not seeing, that we don't curtail it. So I tend to, in many instances, say, okay, let's give it the benefit of the doubt. Because if it is correct, it's going to be much more transformative than if we just continue doing science that follows the rules of the game very, very precisely where basically what you are expecting, you've already seen. So I do think that we need to push the limits with open access to scientific databases. This is happening more and more, which is very exciting. Now, as you mentioned, you have perseverance as a superpower.


Instilling perseverance in younger scientists. (28:32)

It is just a statement of reality that you don't stop. And some people may not have that constitutionally when you are mentoring or having conversations with, say, younger scientists who are facing their first pushback, they're getting rejected, they're having to try again and again. Maybe they're feeling demoralized. What do you say to them? I say, you know, this happened to me. I mean, my first grant was basically just red line, totally and absolutely. And I was very depressed. And at that time, actually, people in the institute at NIDA said, Nora, try again. And I was in that respect. And again, I do not take no for an answer. And this is a message that I say to young people, you should dare to do things. And no one has the right to say, you cannot bring a new perspective into things. And so I always say be daring and persevere. I mean, with all of my postdoc students, they get rejected on a paper. They get rejected on a grant. I mean, the answer is just stand up and jump back on the horse. I mean, it's just like as simple as that. And for those who who aren't watching any video, you are very tough. You're very physically fit.


Dancing with Demerol. (29:58)

You're very mentally fit. And you walk the walk. So I want to just give people further evidence that you very much walk that walk. And I'm going to say going out to perhaps a discussion of the difference between studying compounds and experiencing compounds. And I was hoping you could tell the story of how you became acquainted with Demerol. It's interesting, you know, because I love Demerol. I probably shouldn't be saying these things. But what happened to me, I was in a horrible car accident. I was the passenger and there was one of those hits that the car, it was I see the car, those are 90 degree flip and the car in the opposite direction comes in and strikes me in the passenger seat. Seeing the car coming to me, I did not want my brain to be hit by a car. And so I said, okay, I put my foot into the car to protect my head and to get my head as far away as I could from the door because I saw it coming. And so I did not get hit in the head, fortunately, but the door was came crashing and I was trapped. My leg was trapped, it was broken. I was under a lot of pain and I wanted to lose consciousness because the pain was so intense. And so they finally, they had to come up with this just of life to open up the door because they couldn't get me, they get me into the ambulance, take me to the hospital. And there the doctor says, Nora, we have to try to move the fracture so that we can accelerate the healing. So otherwise, we're going to have to go for surgery. So we're going to give you Demerol. And they injected me with Demerol. It was extraordinary, not just the intensity of the suffering was disappearing everything was fascinating. And opioids made you sleepy. And I was forcing myself not to sleep because everything was so extraordinary. And so it gave me an insight of how powerful that drug was, that despite everything that was there, I wanted to be aware of every sensation. And they admitted me to the hospital and I had to spend two nights and three days. And I recall I was in terrible pain and they would give me that Demerol. And it was this sense of well-being, extraordinary sense of well-being from the opioid. And that is the only time that I've had a real ability to have a consciousness of how an opioid makes you feel. And so when they discharged me, they discharged me on Monday, the accident was on Friday. I was waiting on the car and I felt all chemical, everything felt very unreal. And the doctor had sent me home with two weeks of medication for the pain. And I stopped, I stopped called Turkey. And behold, I did have withdrawal over the night and it was so bad. I didn't understand at first what was happening. I was restless. It was worse than pain. And sometimes you need to experience these things to understand that because say what can be worse than pain. It was just I could not be comfortable no matter what. So I took one of the pills that he had given me and that was the last I took. And then the physical dependence that was responsible for that withdrawal disappeared. And that's it. That's my story with opioids, which made me very aware that I do not want to be exposed to abuse unless I have horrible pain, because I can see their allure. I can see how someone would easily fall into that nirvana, that chemical nirvana that they create. And that's the story of that demerol. And that's why I say I did, I have to be honest. It was an extraordinary experience for me to have been able to feel what it was, but it was also a very scary one. - Super scary. I had nothing nearly that severe, but I had a terrible shoulder injury that ended up requiring reconstruction.


The current state of addiction in the US. (34:01)

But in the emergency room, when I ended up in the hospital, they were overbooked understaffed. They had gunshot victims and so on who took precedence, of course. And so I was sitting there with my arm dislocated, sticking out of my chest for hours. And they gave me morphine. And I remember thinking two things. The first was, this is incredible. The number two was, I should never ever touch anything like this again. And so after my surgery, when they sent me home and they gave me a Vicodin and this, that, and the other thing, they gave me a whole collection of different painkillers. And fortunately, some of them, I took for just a few days and they made me nauseous. And I was very happy that they made me nauseous, because it made me less likely to use them. But I do have, I suppose, a firsthand acquired fear, and then a developed fear just from the experience of people in my family and my friends. What is the current state? How should people think about the current state of addiction and overdose crises in the US? - Well, it's unfortunate. I wish it were different, but it is in a state of very severe overdose deaths that are very difficult to control and regulate. And what we are observing is that we are seeing more and more people dying with very diverse demographics from overdoses, which, again, makes it so very hard to control. Because at the beginning, the crisis started because we started to overprescribe opioid medications and people diverted them and people also who should have not been given them, because they didn't have severe pain syndromes, became addicted, and that opened up the door for heroin. And then we started to see a rise in 2011, more or less, of heroin, injection, heroin, and people dying. And then in 2016, there was a transformative, very malignant change, which was the introduction of fentanyl. And fentanyl, we all been hearing about it in the news, is a synthetic opioid that was developed in order to have a more potent analgesic, is widely utilized in medicine for breakthrough pain, for cancer patients, for example, when the medications that they have no longer controls the pain, you can use fentanyl. But it's also widely used by anesthesiologists, because when you combine fentanyl with an anesthetic, you actually can control and regulate much better the level of consciousness of your patients. So it's a very useful drug. But it is by its potency, it is highly highly addictive. It's also highly dangerous because of its potency, it can make you stop breathing very, very rapidly. And it's a drug that is very cheap to manufacture. You don't need to cultivate any plant. You synthesize it, and the synthesis is very simple. And because it's so potent, you need 50 times less volume of drugs, so you can bring it through the borders much more easily than with heroin or any other drug that we know of. And so it has both pharmacological effects that make it dangerous. But also the production makes it actually very enticing for the drug dealers, so they are incentivized to distribute it. And that's what we've seen, accelerated during the COVID pandemic, basically fentanyl permeated all of the country everywhere. And so they started to also mix it with other drugs like cocaine or methamphetamine. And now more recently, with counterfeit pills that are sold like other al, which is an amphetamine or like Ativan, which is a benzodiazepine that you use for anxiety or sleep, or even these guys as Vicodine, which is an opioid medication for pain, they sell them on the web and they are less expensive than the real thing. So people, it's not just that people that are addicted to opioids, can overdose. Now those that are taking cocaine can overdose, those that can take methamphetamine can overdose. And students that may buy a pill in order to study for an exam may overdose and die because the pill they got had fentanyl or a person cannot get their physicians to prescribe them a sleep medicine, they go and buy it on the web and they overdose. So this is the nature of the major challenges that we have. And we're seeing more and more new substances emerging, which is like again, running in a treadmill because we develop antidotes for the overdoses from fentanyl. But now they are mixing fentanyl with an aesthetic that is using veterinary medicine, silosin. And that actually silosin does not respond to Narcan, which is the antidote that we use for fentanyl. So this shifting nature of the drugs that people are exposed to, the fact that they are increasingly more potent. And the fact that they are basically disguised in many ways is expanding the number of people that are now overdosing. And in some instances, we don't have good strategies that we can use to help them to reverse those overdoses. Yeah, it's such a complex evolving ecosystem of compounds. And as you mentioned, there's so many incidental or accidental ways to ingest, for example, fentanyl.


The War on Drugs. (39:43)

And I know of many direct stories where people have gone to a bachelor party, they try a little bit of some drug that ends up being cut with fentanyl. I know of two people specifically, one just dropped dead on the floor, one fell into a coma from what would have been considered low doses of illicit drugs, but they have to be cut with fentanyl, which is horrifying. And in fact, my friend who died was not himself an addict. He was collateral damage. One of my other friends I grew up with, there are a lot of drug issues where I grew up was a heroin addict. He had developed just an incredible tolerance to fentanyl. And he gave it to my other friend to help with his hangover. And my other friend had never used any opiates and he fell asleep and just never woke up. So the the sheer ease with which the fentanyl, as you mentioned, sort of permeates different corners and neighborhoods of society, and which does not discriminate in terms of, or I shouldn't say it doesn't discriminate, but it has infiltrated every socioeconomic class. It's really pervasive and really terrifying. What is your perspective on the war on drugs and perhaps any other approaches that you think may be more effective? I'll answer it, but I guess actually the story that you just told of your friend that how he by taking fentanyl on the knowing what it was, you just kill him. And this is what we are observing a lot. And I think it's important to educate people that this is a seriously dangerous drug. And I unfortunately, I think that we have cried wolf so many, many times that we've lost credibility. But if there was a way that we could convey that in very objective, we don't need to exaggerate in any way. I mean, fentanyl, it's two milligrams will kill you. And the counterfeit pills contain five milligrams, some of them, two doses to kill you. So it is very, very tragic. Coming back to your question in terms of the war on drugs and the war on drugs, I think that basically what it did was it created a mechanism that could perpetuate structural racism. It is very tragic to see how its enforcement led to the incarceration of young black Americans. And again, that system, that punitive system where someone could be stopped and this will happen if you are black and on the notion that you had drugs with you and thrown in jail or prison because you had drugs on you, it's such an unfair system. And it didn't work in any way because it did not reduce the amount of drugs that people were taking or the negative consequences to drugs to our society. So it did not work. And I think one of the aspects that it did show is if you do throw a person that's taking drugs in jail, if you criminalize that person that's using drugs, like for example, we did horribly with crack cocaine. So if you were smoking crack cocaine, it was like, I don't recall exactly, but it was at least 10 times greater penalty that if you were just snorting cocaine, snorting cocaine or injecting cocaine, hydrochloride was much more favored by white people whereas crack was favored by black people. So cocaine, hydrochloride white, crack cocaine black, why do you see such a difference in it is the same cocaine, basically it's cocaine is cocaine and yet one called noted a much higher penalty than the other. That's an example of the consequences. But what science has shown is that when you do throw people into jail or prisons that have a problem with substance use disorders, then when they leave, they are at much greater risk of first of all, relapsing immediately into the rock taking and escalating their drug taking. So you are exacerbating the nature of the problem by putting them in jail and prison. So it doesn't work no matter what you do. And that's why the whole notion of criminalizing the person that takes drugs is basically very negative vis-a-vis the outcomes of the person and also in no way is the benefit society. It is actually very costly by itself. When an issue becomes politicized, it becomes much harder to change and shift. And we've seen, I mean, I think that we've seen over the past, I would say certainly five or eight years, an openness to recognizing that the war on drugs did not work and that criminalizing drug users is basically a negative and it's promoting structural racism. So I'd like to cover quite a few things. I would like to get to harm reduction. I'd like to do that a little bit later and to hear your perspectives on that.


Increasing societal confidence in therapeutic psychedelics. (45:24)

First, I wanted to go from the problems that you've described to looking at pushing the limits, daring to do things, some of the perhaps novel or developing potential approaches to treating addiction. And there are several things I'd like to talk about. Certainly you have recently, I want to say, written about TMS and deep brain stimulation. I would like to talk about those. First, I thought we might speak about psychedelics and psychedelic assisted therapy. And I wanted to congratulate and thank you for being one of the first, if not the first Institute Director to fund psychedelic research with humans after the scientific winter following the Nixon administration, which interestingly enough, at least I've read that some of the controlled substance act and Nixon's decisions around that were motivated by controlling certain demographics or having the pretense of being able to search and seize and so on. That was from, I think it was Erlichman in his, I might not have been cabinet, but sort of inner circle. But coming back to the treatment side of things, could you speak to perhaps what we know already about psychedelics as treatments? What is interesting? And what milestones? I think this is a question on a lot of minds and you're very qualified to speak to this, what milestones still need to be reached to instill confidence in these drugs as therapeutics. I think it's a very interesting potentially promising area of therapeutics. The way that I see it is the evidence that exists is very limited, but is sufficiently intriguing that you cannot ignore it and behooves you in terms of why we are identifying this as a priority area of research in the whole issue of psychotherapletics of the use of psychedelic drugs. The data is strongest for the use of psilocybin for depression. So, it's have shown and I think that even though the sample sizes are not very large, they have consistently shown improve the outcomes on patients with terminal illnesses. Most of them, I think, if I recall correctly, were with cancer in whom the psilocybin allowed them to accept better emotionally the fact that this was a terminal illness and improve their depression scores. And that was quite significant. There's also data showing potential for PTSD, the use of psychedelic drugs. So, this may be the two disease conditions for which there's more data. The clinical trials are limited in sample sizes and in numbers, but the effect sizes are significant despite the small sample sizes. There are some studies that have been done in substance use disorder. Nicotine is one of them. Alcohol use disorders. Alcoholism is another one. And again, both of them are on psilocybin and for both of them, there is also this positive effect. And what's intriguing and speaking about it in terms of the nicotine is that the effects actually appear to be larger than the ones that you see with medications that we use for the treatment of nicotine dependence, just like chan ticks or nicotine replacement therapies. So, the number of people that stops smoking is actually significantly greater than that. That is the percentage that stops smoking with medications that have been approved by the FDA. But it's a study number one, only one study and the sample sizes are small. So, that's why we're funding the researchers. This is a group at John Hopkins University to actually replicate that study. So, the data is quite interesting, but it is very preliminary. And I do want to emphasize this because sort of people like to make conclusions before the evidence is out there. And my concern is that, and you already see it, you go into the web and there's a lot of sites advertising treatments with psychedelic drugs, not just for mental illnesses, but for also for well-being when the data is not there. And so, we don't know, first of all, if we need to replicate, but assume that you replicate and it does work, what are the doses, how to give it, what are potential negative side effects? I mean, what clinical trials have reported is in a small number of people, there is a risk of suicidal behaviors and so, it's a reality. So, who is at risk to show that? How do you actually, if you start to see it, how can you prevent it? How should you administer the psychedelic drug? It has been believed that the psychedelic drug is a junctive therapy, that it is the interaction with the therapies while you're under the influence of the psychedelic drug, that it is therapeutic, that's one of the hypotheses. So, how you should be administering, how do the psychotherapists get involved? And all of these are scientific questions that we need to basically explore with research because we don't have the data there that is needed to build up. And if we don't build up and people start to use it and they start to have negative effects like suicides, then that can lead to actually the jeopardizing the future use of these medications. The FDA may say, this is too dangerous or the DEA may say, this is too dangerous. We are not going to agree to its utilization. And that is where the danger comes around of pushing something too preliminary. I agree that certainly the positioning of psychedelics as panacea, which we see a lot, is really putting the cart before the horse in a lot of ways.


Advice for researchers seeking more federal funding. (51:49)

And there are risks, which is why there are exclusionary criteria at places like Johns Hopkins for certain conditions, whether it's schizophrenia or bipolar disorder or others. And I'd love to chat a little bit about study design and what researchers might do or consider to make their studies and grant applications more appealing to institutes like NIDA. And the reason that I'd love to explore that a bit is many smart scientists are now paying attention to this, including younger scientists who are considering this as a career focus. And as it stands right now, there's a very small pool of serious independent philanthropists or foundations who are providing funding. It's very small. I would say it may be in the 15 to 20 person range, really, when we're looking at anyone donating above $100,000 a year, it's very small. And then on the other hand, you have, and I think there's a role certainly an important role for market-based for-profit solutions and providers, but you have sponsored research on the other end of the spectrum. And NIDA has been very forward-looking in the sense that you've provided funding to Dr. Matt Johnson and so on at Hopkins looking at nicotine addiction. I would love to know, and I'll just provide a little bit more thought. I know this is going to be a very long question. And then to get your thoughts on what people might do to make their applications or studies more appealing. One of the challenges is certainly that is brought up oftentimes is blinding. And these studies or these compounds and the experiences associated are really highly discriminable in the sense that most people know they are either in the control group or not. And you have potential active placebos and people have experimented with NIDA's and some people have considered higher doses of say cannabinoids. But it's difficult, it seems to find look-alike drugs that do not also bring similar actions or effects. Do you think there's a place for say, comparative efficacy studies where you might have a bi-analogy psychotherapy versus X, right? The people who are getting psychotherapy are going to be aware they're getting psychotherapy, but you could compare it with another therapy where you could compare psilocybin for say, nicotine addiction to nicotine replacement therapy. Those are just a couple of, I suppose, a bit of connective tissue for people who may not have more context. But what would you like scientists to pay attention to? What would you implore them to try to do with their studies and designs if they want to try to get more federal funding? Well, I think that certainly you've discussed and there's no simple solutions of how difficult it is to control for a placebo. But it is an important one. So, one of the recommendations is to use a very low dose of the psychedelic drug. So, you are giving them the psychedelic drug, but a dose that is considered to be super therapeutic. And that's what some of the researchers are doing right now. And to follow all of the guidelines and practices when you are doing, if you're going to be doing a randomized clinical trial, which are the ones that you basically divide, participants, some get the active intervention, others do not, and you randomize it, and you follow them. And that's the way that you actually collect data that then allows you to determine if there is a difference or not. But I think that the grantees that are coming up with proposals know this. I mean, how to propose one of the randomized clinical trials. One of the things that we work with grantees to, which is important, is that we help them in terms of the interactions with the FDA. Because the FDA, at the end of the day, is the one that's going to be able to say, what data do they need in order to be able to consider that a clinical trial is done in a way that they make it feel comfortable to approve an indication for a psychedelic drug or not. So, it is crucial that they work with the, from the beginning, as they are planning to do their clinical trial, that they engage with the FDA. And we absolutely help them. I mean, we try to provide them support in if the FDA, for example, wants them to do toxicology X or toxicology Y or look at the bio distribution. There are certain things that we can, through our contracts, help them obtain. And we are specifically requesting this, and I'm speaking right now of clinical trials if grantees. There may be other scientific questions that are very valid that are not just a randomized clinical trial, that we also would be very interested on funding, for example, with brain imaging, you can now look at how, and there was a paper, there's one paper that actually look at the effects of psilocybin. I think it was psilocybin either LSD or psilocybin, I don't recall. And you are looking at, we have these brain networks that interact with one another. And what they showed was that that architecture of network was significantly disrupted during the hallucinations that when the drug was on board. And so if you can do research that can identify biomarkers of the effects of the psychedelic drug, that's one area that we're interesting. But also through those studies, can you understand the mechanisms that are responsible for the therapeutic benefits? So by looking at how the brain changes its operations, and then you can determine if that is associated with the therapeutic benefit, you can start to understand mechanisms of actions of psychedelic drugs. We're also funding researchers to develop, we know what the psychedelic drugs that we currently have. But with chemistry, you can create other psychedelic drugs, for example, that may have the same pharmacological target, but they don't produce hallucinatory experiences, which would make it much easier to actually implement. So we are interested in a whole gamut of research that could help advance our understanding of the potential of psychedelic drugs for therapeutics. The entire category of non-holicinatory psychedelic compounds is very interesting.


Gauging the value of the hallucinogenic experience. (58:54)

There appear to be some very interesting indications that might be really favorable targets for these, what are sometimes called the cycle plastigens, like cluster headaches in the case of LSD or LSD analogs. What would you make? And the answer could be that they're mistaken of researchers who report based on all the documentation from subjects in these various studies, whether at UCSF. And I think the imaging that you were mentioning may be Robin Carhart Harris and his team, because they do a lot of functional MRI and imaging, looking at the perhaps increased entropy or connectivity or both communication-wise in the brain on these experiences. And in that case, it would be psilocybin or psilocybin. And what would you make potentially of the importance of meaning making? And that is to say, beyond the activity signature that you can track or the receptor affinity, the reports from subjects that it's the meaning making in these sessions, which seem to be in part hand-in-hand with the hallucinations, the psychedelic experience, relating to how they see themselves and the world that lead to the behavioral change and the durability of some of these effects. Rather than dendritic spine growth or any number of changes that you can observe, but given that the duration of some of these sessions, four to six hours, let's just say, and the half-life is pretty short, but some of the effects seem to be quite durable with, say, the existential distress and terminal cancer patients and also for nicotine. Is there a way to include those factors as an area of inquiry in addition to the sort of mechanistic studies and the basic science and the imaging? Of course, and there's been actually papers that have done that actually have looked at the association between the intensity of the subjective experience and their therapeutic benefits, and that have shown that those that have the more intense mystical experience had the better therapeutic response, but that element of meaning and understanding is basically not in any way exclusionary with that of neuroplasticity, because it may be that, in fact, that experience that you have there while you are living it under the effect of the hallucinogenic growth may generate a longer lasting memory because of those neuroplastic effects. And again, highlighting why that combination of the drug itself with a psychotherapeutic intervention becomes crucial. So you cannot certainly separate them. I mean, to me, if it can be corroborating that there is this neuroplasticity and we learn to use it properly, then imagine how extraordinary it is to be able to generate a window in time where, by exposing you to a stimuli under the effect of the psychedelic drug, if it, in fact, turns to be the case, you could strengthen a particular memory, and that would allow you to actually cover a memory that may be very painful. So you are competing one memory against the other. So I think that this is to me one of the most fascinating areas about why I think that these psychedelic drugs deserve attention for research. Because to have a means to monitor to accelerate learning and memory process, this neuroplasticity long-term potentiation phenomena that we've been studying in neuroscience would be a very powerful tool. Yeah, it's been very exciting to be involved with some of the early stage science and to see it develop over time and to also have a lot of misgivings about the public discussion when it veers into the land of panacea because these things are absolutely not panacea and they're very, I believe, powerful compounds based on the data that we have so far.


Exploration Of Alternative Therapies

Implications for multiple applications of one compound. (01:03:04)

One more question, maybe two more questions about this and then I would love to move to TMS, which I am increasingly fascinated by. I was a subject in a study involving TMS a long time ago, but the technology was pretty primitive then. My question is about substance use disorders and the very preliminary, but very preliminary hypothesis that psychedelics and specifically psilocybinos. The same molecule appears to have effects across drugs of abuse, meaning or potential abuse. If you have, let's say, the work of Michael Bogan shoots and others at NYU looking at alcohol use disorder psilocybin, then you have Dr. Matt Johnson and nicotine. You also have people like Peter Hendricks looking at cocaine. If it turns out that those can be replicated, we can hopefully, and I'm very optimistic that there'll be more federal funding for these things, because there is a bit of a chicken and the egg problem in terms of sample size and funding availability, which is challenging. But what could it mean if it turns out that something like psilocybin is effective across multiple compounds? Is that common? I simply don't know in other sort of frontline treatments, or would that be something novel that would raise very interesting questions in your mind about the nature of addiction? I've been studying as a researcher multiple addictions in cocaine, alcohol, methamphetamine, nicotine, and more recently opioids and heroin also. I've been intrigued about what do all of these addictions have in common? In fact, I've been intrigued about what something like morbid obesity has in common with addiction, if you look at the brain, because they all share as a common phenomenological presentation the compulsiveness of the behavior and the loss of self-regulation. So you cannot stop it, and you just basically escalate on that behavior. So I've been intrigued about recognizing the common elements in the brain, and then of course studying also their uniqueness. But there are the neurocircuitaries basically very similar. What is different is the way that you engage it. So to me, in and of itself, it's not surprising that you have a therapeutic that is going to be valuable for multiple addictions, and we're funding other type of research with other molecules with the aim of basically targeting just a medication for addiction in general, so that we could also start to address the problem of polysubstance addictions that we have, without having to just go specific. So it doesn't surprise me. What I would be very intrigued in that notion is if we were to understand the mechanism, and the common mechanism across all of the addictions is that you create long-term potentiation in reward circuits. So you are strengthening the signaling on systems that basically are associating the drug with pleasure and reward, and you are weakening the signaling that's associating pleasure and reinforcement for other stimuli and reward. So just actually, as strengthening processes and a weakening processing, and you generate it in such a way that you've created an artificial need for the drug, just like you have a need for food, now you have an artificial need for the drug. And I'm very much intrigued about the similarities with pain. When you have pain where the insult is no longer there, but the memory of that pain continues making you feel it. Just like in the addicted person, the memory of the pleasure leads you to continue wanting it. So it's not just that I think it could be beneficial for different types of drugs, but I do think there's value in actually even considering the extent to which if they are shown to be able to modify neuroplasticity, treatments for discronic pain conditions, which are devastating and for which you really don't have anything. I mean, not that I know that there's much researching to it, but I just telling you where my brain is jumping into. Yeah, absolutely. So a few things come to mind. If you haven't looked at the work of Ghoul Dolan, G-U-L-D-O-L-E, and she's at Hopkins, her perspective is quite different from say Robin Carhart Harris, and I think she has some very interesting hypotheses around these windows of reopening of critical windows with respect to, say, plasticity. And then on the chronic pain topic, I will say, and this was done at a above board, very well run clinic with proper medical supervision, but I went through two weeks of ketamine infusion several years ago, not because I was depressed, but because I wanted to be able to speak firsthand to the experience because I knew I would have a lot of questions about it from friends and also audience and so on. I'm not a doctor, I don't play one on the internet, just to be very clear, but what was fascinating to me is I went in having read a lot of the research related to depression, and I've since had Dr. John Crystal from Yale on the show to have a very long conversation about all things ketamine. What I didn't realize though when I went in, because I was not going in with any severe depression, is, or I couldn't have anticipated what happened. And that was for me, I had chronic back pain in my mid thoracic back from a long standing injury, which was very severe, had daily pain and tense pain for 10 years, let's call it. And when I left my two weeks of infusions, I had no back pain for about six months. And it turns out one of the other primary indications is chronic pain. So there's a lot to recommend psilocybin over ketamine at psychedelic dosing, but it matches very well with what you were saying about the potential overlap of plasticity and not just for indications like depression, but also for something like chronic pain. Yeah, no, and I wasn't thinking of ketamine because I wasn't thinking, I mean, ketamine is not considered as you know, a classical psychedelic drug, but there is a lot of work on research ongoing for the value of ketamine for the treatment of chronic pain. What I would like to sort of look, and I look at it in terms of what has been done, because again, this is all of these areas are under under investigated, but I'm going to check it out because I want to be to see if anyone has published anything on psilocybin for chronic pain. So I was jumping into the classical psychodelics, which have very different mechanism of actions than ketamine. But absolutely ketamine. And I think ketamine was the drug that let us open up the doors to say, here we have a drug that nobody that is a dissociative type of drug, that it's also a drug that has that can produce addiction, a psychodelic classical psychodelics stone. And yet despite everybody's prejudices show to be beneficial for treatment of depression. So I think that that is an example about why we cannot just close our eyes and say, no. And we need to look at these classical psychodelics. So I would like, you made me now curious about it, but I suspect also the fact, as you were mentioning earlier, that there may be is room for potentially stripping out some of the psychedelic effects. I think we need to keep in mind that the business motivations may not always be aligned with clinical outcomes.


Transcranial magnetic stimulation (TMS) and a promising alternative. (01:11:15)

Of course, it would be much more convenient to work with these compounds if they didn't elicit the types of hallucinations we've discussed. But even something that is non classical psychedelic, let's say, salvin or an A, right? So you have a cat, opioid agonist, may have some really interesting applications for minimizing damage after stroke, for vascular problems. Super, super fascinating. Of course, more research is needed. So I wanted to shift to TMS and deep brain stimulation. And this is very interesting to me. We were talking about sort of different activity or maybe pathological activity in different neuroantomical structures. I don't know if the nucleus cumbins fits into both that prior discussion and the TMS and deep brain stimulation. But could you speak to what TMS is, what deep brain stimulation is, and why they are of interest? Oh, they are incredibly interesting. I'm going to introduce you to a new technology that has my brain even more excited than TMS. TMS goes for transcranial magnetic stimulation. An ESA technology that is not invasive, you actually administer magnetic currents in the SCAP and then these magnetic currents actually go into the cortex of the brain and they are signal transferred as electrical signals. And it can be used to modulate either at high frequencies to stimulate or sort of lower frequencies to inhibit the areas that you are targeting. And by understanding how in the cortex, because the cortex, I mean, the brain is a very complicated network. And so it links with almost everything else, but they are hops, they are areas that act as hops, that is, they have many more connections. Some of them go deep into the brain. So as you understand better that pattern of connectivity, you can deliver TMS in such a way that you can start to reach areas that are deeper in the brain, which are very important for diseases of depression and diseases of, of certainly addiction. I mean, you were speaking about the nucleus accumbens, which is the main required region of the brain and all of the drugs of abuse, all of them stimulated. And when you stimulate the dynamics with electrical currents or with optogenetics, you generate rewarding signals that transcranial magnetic stimulation cannot reach deep, but you can reach it indirectly. And that's what they use it. And it's a technology that's approved for the treatment of depression. Deep-range stimulation, then basically is an invasive procedure. You put the electrodes inside the brain and the treatment of, it's being used, for example, for treatment of addiction research. It's being used for research also, treatment of depression and other diseases. And the nucleus accumbens is one of the main targets, both for depression as well as for addiction. But there are other neuromodulation technologies, so transcranial magnetic, the other one is direct electrical current stimulation, which instead of giving magnetic signals from the outside to give electrical pulses. But the one that I am very intrigued and I want to actually introduce you to it. If you haven't heard about it, it's low, low intensity ultrasound. So it uses ultrasound. And if you can use it with high intensity or low intensity, and you apply it on the outside of the brain, if you use high intensity, you can very specifically create an ablation. So you can do what you could do with surgery, but very precisely without having to open the hair. But that's high intensity. The period of the low intensity is you do not produce damage to the tissue, but you can modify it for a long time. So they are doing research right now. And the high intensity ultrasound was recently approved for Parkinson's disease. And they are high intensity. The high intensity. But the researchers are looking at low intensity for neurological diseases and for addiction and other mental illness. And the beauty is that sound goes through the tissue so you can target your nucleus accumbens directly with a much greater precision that with transcranial magnetic stimulation. Okay. Yeah, that's super interesting. It's fascinating. And you need to apply it for 10 minutes. And the pilot data is showing that you see it for say, the effects are two weeks or four weeks with a single stimulation. With a single session of 10 minutes. Yes. Wow. Okay. That's very interesting. It's pilot data. That's why I say now that you're speaking to me. And last time we spoke, I was I'm very excited of TMS. I'm not in any way going to minimize it. But actually, what I like so much, and I'm just going to say, God, you pushed a limit. And I said, let's push our own thinking. If you are able to do this long lasting effect through this, as you learn to understand better, how these frequencies for ultrasound stimulation affect the tissue, I think that one day we may be able to cure addiction. And no one has ever heard me speak about cure addiction. Yeah. So why do I think it is possible? Because we know that when people have strokes in certain areas of the brain, particularly frequently involving the insula, there are cases where people just stop taking the drug. They forget about taking the drug. They don't care anymore about it. So there's been instances which have shown that the insult, a stroke in a particular area, cure the person of their addiction. So what about if we gain that knowledge about what are the relevant circuits and areas? And we have the tools now to manipulate them in ways that are much more effective than we had in the past that opens up the possibility of in the future that we may be able to cure addiction. Well, that makes me feel much more optimistic. And I also feel like at some point and I'm getting ahead of myself, but looking at these novel cutting edge technologies, or in some cases, very old technologies like Sillis-Iam being applied to conditions in novel ways, that at some point there might be polytherapies that combine some of these factors.


New hope for Parkinson’s disease sufferers? (01:17:42)

Let me ask you a question about the Parkinson's for a second though, because I have Parkinson's on one, I think now both sides of my family. So it's of intense interest. If they're using high frequency, and for those who don't know the term oblation, and I want you to please correct me from wrong, with that can be surgical removal of tissue, or I suppose destruction of tissue, might be another way to put it. I want you to correct my definition if I'm getting it wrong. But how would that strength of effect be used in Parkinson's? It is the high intensity ultrasound and the high intensity ultrasound becomes ablative. So you are targeting, for example, the subthalamic nuclei, just like you do with surgery. But in this case, you are not opening it up and you can very precisely damage it. So this brings psycho surgery to a completely new level. And so they applied it. And they are also, I think that one of the targets is a subthalamic nuclei, but I also think that they targeted parts of a very small nuclei in the thalamus too. So it is fascinating also from that perspective of instances where psycho surgery may be valuable, that you can do it as minimally invasive and as precisely and as small at areas possible. So I think it's quite remarkable. Now you got me all excited about this low intensity ultrasound. I've been following the TMS pretty closely. And in particular, the shorter duration, higher frequency dosing of TMS, so let's just say multiple sessions a day over the span of five days, there's some interesting work being done. And certainly, I know the plural of anecdote does not equal data, but anecdotally, I've seen a number of outcomes with friends, children who are patients that have practically just defied belief. But on the low intensity ultrasound side, you mentioned, and we'll put links in the show notes for people and maybe I'll get some links from you or your team just where people can learn more about this. I know it's pilot data, so you can hold your horses, the jury's still out, but nonetheless, very interesting place to begin is the, in addition to the durability that you're mentioning, which I think was two to four weeks, let's just say after a single 10 minute session, is the onset of effect immediate or near immediate as well? It's basically almost immediate. Wow. And one of the consistent findings that they are seeing is that there's a reduction in anxiety, they see a reduction in craving. And it's pilot work, I want to reiterate that it needs to be replicated. But you know, when I saw that pilot data, I said, oh my God, and it was the group that was Virginia, who has been doing the cycle, basically the deep brain stimulation for the treatment of opioid addiction. And they insert these electrodes, and then they've basically observed that in three of the four individuals that they've treated on that pilot study, they basically, they were able to again very dramatically reduce anxiety, and they decrease the consumption of opioids. So it showed a positive effect in three or four. And they, I mean, they basically told me these effects that we're getting with a low, low intensity ultrasound that they've tested eight people are as dramatic or more dramatic that one we're seeing with basically the deep brain stimulation of the nucleus accompanist. So they target also the nucleus accompanist with low intensity ultrasound. So it's very intriguing. I'm a scientist and I love and I get excited with data, but I do want to reiterate, it's very pilot, it's very, very pilot, but it has to be studied. It's like with, what we were saying with the psychedelic drugs is very interesting, it has to be studied. Yeah, everything starts small. Almost everything starts small, right? We all start with the pilot.


Final Thoughts On Comorbidity And Addiction

Comorbidities, addiction considerations, and other parting thoughts. (01:22:03)

So the jury is still out, but it's exciting that you're pushing the limits and you're daring to push the envelope and experiment with new things. Of course, I mean, that's part of the charter, but you also have a history of doing this well. And I don't think you would have arrived where you are today had you not been very dogged and determined. Yeah, it just goes, goes all the way back to when you were, you were turned down by NIDA. And here you are as the director. It's just remarkable. It's just a remarkable story. So Dr. Volkoff, even very generous with your time, I've enjoyed the conversation. I could keep going for another two hours, no problem, but you have an incredibly busy schedule. Is there anything else that you would like to share with people out there, any requests to my audience, anything at all that you would like to say before we wind to a close? There are two things that I would have liked to add. One of them is that addiction is very frequently comorbid with other psychiatric disorders and most notable is anxiety, depression, suicidality. And I bring it up because you need to address these comorbid conditions, because otherwise it's not going to be possible for the person to be able to recover. And also from the perspective that if you are depressed, if you are anxious, if you are suicidal, you are likely to take drugs as a mean to auto-medicate, to escape that mental state. And it is crucial to send this message because it's not as simple as saying that you take drugs because you want to get high and you're taking the drugs. People are taking the drugs too many times, initially just for curiosity or many times to feel good. But once you become addicted, it is really to escape a mental state that is very difficult to stay at. It's very in a way very painful. And the other point that I did want to bring to that we haven't discussed, which is in understanding how we understand the effects of drugs and addiction and how we understand also mental illness, is how important the environmental factors are and how crucial they are, particularly where when you are a child or another lessens. And that I think that we've all become much more sensitized to them with a COVID pandemic because we came to realize that there are certain people that were at much greater disadvantage. And that's those that deal with people that are in circumstances of economic inequality, of trauma during childhood. And what we call the social determinants of health that are really playing very important roles in people's encounter with drugs and how they respond to it and how they ultimately also may be given an opportunity or not to access treatment and to how they respond to treatment. So as you were speaking, for example, with psychedelic drugs, we are very concerned that if a psychedelic therapies, if they basically get into a mainstay clinical practice, if they are proven to be useful, that they are equitable. And in the it doesn't end up like many of the very fancy treatments that we have now that are only accessible to a very few. So that's the only other thing that I would want to say. 100% agreed on both. And that's also part of the reason that I hope we will see whether it's with psychedelic therapies, psychedelic assisted therapies, or other modalities. In some cases, options for group treatment. And at least the testing of the hypothesis that outcomes can not only be equal to individual treatment, but potentially even better. And I think there is the possibility that that is the case, which would also have the wonderful side effect of decreasing costs quite significantly. And there's so many questions of insurance reimbursement and ultimately reclassification, which would be sort of a precursor to a lot of these things happening. But I agree with you absolutely completely. And it's also as upsetting and pessimistic as one can become when they look at the compounding of many of the addiction problems in the US. I feel like we are at a point in history also with some of these burgeoning technologies. As you mentioned, and I think it was obvious in the excitement in your voice, I mean, there are things potentially on the horizon that could really change how we not only treat addiction, but how we think about addiction as well, which is very exciting. And I think cause for a certain degree of cautious optimism. Oh, yes, I'm very optimistic. The man, I'm going to abandon you at this point. I'm going to jump off that screen. But it's been a pleasure speaking with you. Thank you.


Great! You’ve successfully signed up.

Welcome back! You've successfully signed in.

You've successfully subscribed to Wisdom In a Nutshell.

Success! Check your email for magic link to sign-in.

Success! Your billing info has been updated.

Your billing was not updated.